QualityDipStocks / Health Care · Biotech
ImmunityBio IBRX
Outside our quality screen, so we don’t track its dips. It’s 31% below its 52-week high.
Outside our quality screen, 9% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 36% from its 52-week high while revenue grew 193%
- Revenue up 193% in a year, top 1% of the 1820 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $8.73price −9%
- Off 52-wk high
- −31%
- Risk vs market
- Highbeta 1.64
3 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for IBRX: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much IBRX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 8.4× the S&P 500’s.
- Beta vs S&P 500
- 1.64
- Volatility
- 107% vs 13% SPY
- Correlation SPY
- 0.20
- Correlation QQQ
- 0.20
How it ranks
Where IBRX stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield−3.4% · free cash flow vs market capLowest 10%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+193% · vs the 12 months beforeTop 1%of 1,814
- Operating margin−152% · of sales kept as operating profitLowest 1%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $8.73
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
GrowthSales grew 193% to $166M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityGross margin of 99%, above the 62% median for the 146 Health Care companies we cover.
ValuationTrades 9.0% below its Market Value of $8.73, the average price paid since the Aug 4 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$288M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $992M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 18.2% in a year: existing holders are being diluted.
ProfitabilityLoses money at the operating line: −152% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; no return-on-capital data; debt load unclear or high.
All fundamentals
FCF yield -3.4% · Sales +193%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −3.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 50.67×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $8.4Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $166M
- Sales growth, 12 months
- +192.9%vs the 12 months before
- Sales growth, 3 yrs
- n/an/m
- Diluted EPS, 12 months
- −$0.95
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$992M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 99.3%
- Operating margin
- −151.9%
- Net margin
- n/an/m
- FCF margin
- −173.8%
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $357M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$288M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +18.2%diluted shares vs a year ago
- Stock-based comp
- $34M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From ImmunityBio’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.3B · Sales +94%
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield-3.4%
- Gross margin99%
- Operating margin−120%
- Sales growth (latest quarter vs year-ago quarter)+94%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $7.95
- 52-wk lowlowest close, 1 year$1.98−75.1%
- PriceMon Nov 2 close$7.95you are here
- Market Valueavg paid since Aug 4$8.73+9.8%
- 52-wk highhighest close, 1 year$11.55+45.3%
Momentum & 52-week range
RSI 41 · 5 days +1.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3
- Consensus EPS($0.08)
- Year-ago EPS($0.07)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
IBRX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on ImmunityBio in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.